These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 23012408)

  • 21. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
    Miao H; Choi BD; Suryadevara CM; Sanchez-Perez L; Yang S; De Leon G; Sayour EJ; McLendon R; Herndon JE; Healy P; Archer GE; Bigner DD; Johnson LA; Sampson JH
    PLoS One; 2014; 9(4):e94281. PubMed ID: 24722266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors.
    Tamura K; Wakimoto H; Agarwal AS; Rabkin SD; Bhere D; Martuza RL; Kuroda T; Kasmieh R; Shah K
    Mol Ther; 2013 Jan; 21(1):68-77. PubMed ID: 22929661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
    Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS
    Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of miRNA-7 by genome-wide analysis as a critical sensitizer for TRAIL-induced apoptosis in glioblastoma cells.
    Zhang X; Zhang X; Hu S; Zheng M; Zhang J; Zhao J; Zhang X; Yan B; Jia L; Zhao J; Wu K; Yang A; Zhang R
    Nucleic Acids Res; 2017 Jun; 45(10):5930-5944. PubMed ID: 28459998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.
    Jahan N; Lee JM; Shah K; Wakimoto H
    Int J Cancer; 2017 Oct; 141(8):1671-1681. PubMed ID: 28567859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
    Keir ST; Chandramohan V; Hemphill CD; Grandal MM; Melander MC; Pedersen MW; Horak ID; Kragh M; Desjardins A; Friedman HS; Bigner DD
    J Neurooncol; 2018 Jul; 138(3):489-498. PubMed ID: 29564747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells.
    Höring E; Podlech O; Silkenstedt B; Rota IA; Adamopoulou E; Naumann U
    Anticancer Res; 2013 Apr; 33(4):1351-60. PubMed ID: 23564772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-homing cytotoxic human induced neural stem cells for cancer therapy.
    Bagó JR; Okolie O; Dumitru R; Ewend MG; Parker JS; Werff RV; Underhill TM; Schmid RS; Miller CR; Hingtgen SD
    Sci Transl Med; 2017 Feb; 9(375):. PubMed ID: 28148846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma.
    Xia L; Liu JY; Zheng ZZ; Chen YJ; Ding JC; Hu YH; Hu GS; Xia NS; Liu W
    Mol Ther; 2021 Oct; 29(10):3011-3026. PubMed ID: 34058385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic efficacy and fate of bimodal engineered stem cells in malignant brain tumors.
    Martinez-Quintanilla J; Bhere D; Heidari P; He D; Mahmood U; Shah K
    Stem Cells; 2013 Aug; 31(8):1706-14. PubMed ID: 23389839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.
    Eller JL; Longo SL; Hicklin DJ; Canute GW
    Neurosurgery; 2002 Oct; 51(4):1005-13; discussion 1013-4. PubMed ID: 12234411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma.
    Li M; Mukasa A; Inda MM; Zhang J; Chin L; Cavenee W; Furnari F
    J Exp Med; 2011 Dec; 208(13):2657-73. PubMed ID: 22162832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
    Zheng Q; Han L; Dong Y; Tian J; Huang W; Liu Z; Jia X; Jiang T; Zhang J; Li X; Kang C; Ren H
    Neuro Oncol; 2014 Sep; 16(9):1229-43. PubMed ID: 24861878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.
    Conti S; Vexler A; Edry-Botzer L; Kalich-Philosoph L; Corn BW; Shtraus N; Meir Y; Hagoel L; Shtabsky A; Marmor S; Earon G; Lev-Ari S
    PLoS One; 2018; 13(7):e0198627. PubMed ID: 29969452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
    Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
    Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo.
    Maussang D; Mujić-Delić A; Descamps FJ; Stortelers C; Vanlandschoot P; Stigter-van Walsum M; Vischer HF; van Roy M; Vosjan M; Gonzalez-Pajuelo M; van Dongen GA; Merchiers P; van Rompaey P; Smit MJ
    J Biol Chem; 2013 Oct; 288(41):29562-72. PubMed ID: 23979133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tanshinone IIA sensitizes TRAIL-induced apoptosis in glioblastoma through inducing the expression of death receptors (and suppressing STAT3 activation).
    Zhou X; Lv L; Tan Y; Zhang Z; Wei S; Xiao S
    Brain Res; 2021 Sep; 1766():147515. PubMed ID: 33984327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.
    Pozo N; Zahonero C; Fernández P; Liñares JM; Ayuso A; Hagiwara M; Pérez A; Ricoy JR; Hernández-Laín A; Sepúlveda JM; Sánchez-Gómez P
    J Clin Invest; 2013 Jun; 123(6):2475-87. PubMed ID: 23635774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis.
    Bhere D; Tamura K; Wakimoto H; Choi SH; Purow B; Debatisse J; Shah K
    Neuro Oncol; 2018 Jan; 20(2):215-224. PubMed ID: 29016934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles.
    Kaluzova M; Bouras A; Machaidze R; Hadjipanayis CG
    Oncotarget; 2015 Apr; 6(11):8788-806. PubMed ID: 25871395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.